| Literature DB >> 26416333 |
Lihua Lu1, Li-juan Liu2, Wei-chieh Chao3, Hai-Jing Zhong2, Modi Wang1, Xiu-Ping Chen2, Jin-Jian Lu2, Ruei-nian Li3, Dik-Lung Ma1, Chung-Hang Leung2.
Abstract
Group 9 transition metal complexes have been widely explored as therapeutic agents due to their unique geometry, their propensity to undergo liEntities:
Mesh:
Substances:
Year: 2015 PMID: 26416333 PMCID: PMC4586517 DOI: 10.1038/srep14544
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Chemical structures of complexes 1–5.
Photophysical properties of complexes 1–5.
| Complex | λem/nm | UV/vis absorption λabs/nm ( |
|---|---|---|
| 555 | 270 (2.15 × 105), 381 (2.47 × 104)[36] | |
| 590 | 274 (7.98 × 104), 354 (1.13 × 104) | |
| 587 | 270 (6.1 × 104), 337 (1.99 × 104)[37] | |
| 593 | 279 (2.0 × 105), 382 (1.56 × 104), 439 (6 × 103)[38] | |
| No emission | 284 (1.21 × 105), 366 (2.26 × 104) |
Figure 2Anti-bacterial activity of complexes 1–5 as determined by the disk diffusion assay.
(a) The anti-S. aureus activity of complexes 1–5. (b) The anti-E. coli activity of complexes 1–5. (c) The anti-E. faecalis activity of complexes 1–5. (d) The anti-K. pneumoniae activity of complexes 1–5. All complexes used are racemic mixture of enantiomers.
Figure 3Inhibition of the growth of S. aureus by racemic mixture of complex 1 as determined by the broth dilution method.
Results are representative of three independent experiments, and the complete data are shown in Table S2.
Figure 4Cell viability of racemic mixture of complex 1 against A2780, HepG2, SKOV3, HeLa, A375 and A2058 cells as determined by the MTT assay.
Error bars represent the standard deviations of the results from three independent experiments.
Figure 5UV/Vis absorption of 1 (2.5 μM) in H2O/acetonitrile (400:1) at t = 0 h and after incubation for 0, 1, 2, 4, 12, and 24 h at 298 K.